Literature DB >> 21342253

Ten-year quality assurance of the nationwide hearing screening programme in Dutch neonatal intensive care units.

P van Dommelen1, H L M van Straaten, P H Verkerk.   

Abstract

AIM: To evaluate 10-year quality assurance of newborn hearing screening (NHS) in Dutch neonatal intensive care units (NICU).
METHODS: Results of the two-stage automated auditory brainstem response (AABR) screening and diagnostic examination in NICU graduates were centrally registered between October 1998 and December 2008. This registration facilitates screening, tracking and follow-up after abnormal screening results. Outcome measures are referral rates, prevalence rate of hearing loss and (trends of) coverage rates and timeliness of follow-up.
RESULTS: Thirty-two thousand one hundred and two infants have been screened. Referral rates were 9.2% at the first and 26.3% at the second stage. Hearing loss was diagnosed in 728 infants (2.2%). Coverage rates were 98.7% at the first, 92.1% at the second stage, 92.3% for the diagnostic examination and 97.9% for the complete programme. After correction for gestational age, 95.8% of the infants had their first AABR<1 month, 81.8% of the referred infants had their second AABR<6 weeks and 67.1% were diagnosed<3 months. There was a positive trend in referred infants that had their second AABR<6 weeks (p=0.004) as well as in infants diagnosed<3 months (p<0.001).
CONCLUSION: The NHS in Dutch NICUs is effective. Timely identification of hearing loss is improving over time.
© 2011 The Author(s)/Acta Paediatrica © 2011 Foundation Acta Paediatrica.

Entities:  

Mesh:

Year:  2011        PMID: 21342253     DOI: 10.1111/j.1651-2227.2011.02230.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  7 in total

1.  Universal newborn hearing screening with automated auditory brainstem response (AABR) in Hungary: 5-year experience in diagnostics and influence on the early intervention.

Authors:  Anita Gáborján; Gábor Katona; Miklós Szabó; Béla Muzsik; Marianna Küstel; Mihály Horváth; László Tamás
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-29       Impact factor: 3.236

2.  Postnatal risk factors associated with hearing loss among high-risk preterm infants: tertiary center results from Turkey.

Authors:  Zeynep Eras; Ozlem Konukseven; Hatice Tatar Aksoy; Fuat Emre Canpolat; Aydan Genç; Evrim Durgut Sakrucu; Omer Develioğlu; Ugur Dilmen
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-06       Impact factor: 2.503

3.  Neonatal Screening for Congenital Hearing Loss in the North of Jordan; Findings and Implications.

Authors:  Amjad Nuseir; Maha Zaitoun; Hasan Albalas; Malak Douglas; Yazan Kanaan; Ahmad AlOmari; Firas Alzoubi
Journal:  Int J Prev Med       Date:  2021-12-01

4.  Changes in quality of life into adulthood after very preterm birth and/or very low birth weight in the Netherlands.

Authors:  Afra van Lunenburg; Sylvia M van der Pal; Paula van Dommelen; Karin M van der Pal-de Bruin; Jack Bennebroek Gravenhorst; Gijsbert H W Verrips
Journal:  Health Qual Life Outcomes       Date:  2013-03-26       Impact factor: 3.186

5.  Newborn hearing screening and early diagnostic in the NICU.

Authors:  Maria Francisca Colella-Santos; Thaís Antonelli Diniz Hein; Gabriele Libano de Souza; Maria Isabel Ramos do Amaral; Raquel Leme Casali
Journal:  Biomed Res Int       Date:  2014-06-09       Impact factor: 3.411

6.  Comparison of Newborn Hearing Screening in Well-Baby Nursery and NICU: A Study Applied to Reduce Referral Rate in NICU.

Authors:  Pei-Chun Li; Wei-I Chen; Chih-Ming Huang; Ching-Ju Liu; Hsiu-wen Chang; Hung-Ching Lin
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

7.  Analysis of the Risk Factors Associated with Hearing Loss of Infants Admitted to a Neonatal Intensive Care Unit: A 13-Year Experience in a University Hospital in Korea.

Authors:  Kyu Young Choi; Bum Sang Lee; Hyo Geun Choi; Su-Kyoung Park
Journal:  Int J Environ Res Public Health       Date:  2020-11-02       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.